Reducing prostate cancer treatment from 5 to 3 doses of radiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the feasibility of reducing the number of curative radiotherapy doses for localized early prostate cancer from 5 to just 3, using Stereotactic Body Radiotherapy (SBRT). The aim is to ensure that the side effects of this 3-dose treatment are comparable to or lower than those observed in the 5-dose treatment from the UK PACE-B trial. Utilizing the RayPilot HypoCath tumor tracking system, which continuously monitors the prostate's position during treatment, the study seeks to enhance patient experience by minimizing treatment duration while maintaining efficacy. The study is a single-arm Phase II trial conducted at centers equipped with this advanced tracking technology.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* low and favorable intermediate NCCN Criteria patients
* Prostate volume under 80cc
* IPSS under 20
* Q-max above 10cc per second and urinary residual less than 150mls
* No TURP
* No hip replacements
* No previous radiotherapy to the pelvis
* No active second malignancy except skin SCC or BCC for the last 2 years
* No history of inflammatory bowel disease
* No co-morbid illness that would make compliance to treatment difficult
* Able to give informed consent

Exclusion Criteria:

* T3a or above
* Gleason 4+3=7
* PSA\>20ng/ml

Where it's running

• NHS Lothian
  Edinburgh, United Kingdom Recruiting

Study contacts

• Principal investigator: Duncan B McLaren, MBBS — NHS Lothian & University of Edinburgh
• Study coordinator: Richard Allan
• Email: richard.allan@nhslothian.scot.nhs.uk
• Phone: +44 1315371463

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intraoperative Hyperspectral Imaging to guide prostate cancer removal

  This study tests a hyperspectral imaging device during prostate surgery to see if it can help identify cancer at the edges of the removed tissue in men with localized prostate cancer.

  Recruiting University Hospital, Geneva · Geneva, Canton of Geneva · NCT07826858

• Focal Micro-boost Radiotherapy for Localized Prostate Cancer

  This study tests whether adding a small, targeted boost to MRI-visible prostate lesions during moderately hypofractionated radiotherapy can improve cancer control in men with localized intermediate- to high-risk prostate cancer.

  Recruiting Regina Elena Cancer Institute · Rome, Lazio · NCT07792993

• Sonablate HIFU Registry for Prostate Cancer and BPH

  This registry collects real-world data from men treated with Sonablate HIFU to see how well it works and how it affects urinary and sexual function over the long term.

  Recruiting Sonablate · Indianapolis, Indiana · NCT07757490

• Water IV: See if Aquablation helps localized prostate cancer patients choose active surveillance

  This trial tests whether Aquablation therapy can be as safe and effective as choosing active surveillance for men with localized prostate cancer who are considering surveillance instead of immediate treatment.

  Recruiting at 12 sites PROCEPT BioRobotics · Chandler, Arizona and 27 other locations · NCT07650448

• Whole-gland prostate dose boost versus SBRT alone for PSMA-staged localized and locally advanced prostate cancer

  We will test whether adding a whole-gland radiation boost (with brachytherapy or a stereotactic boost) improves cancer control compared with SBRT alone in men whose prostate cancer is confined to the prostate on PSMA PET.

  Recruiting Phase 2/3 Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07426055

• Androgen-guided PSMA-PET-boost for prostate cancer treated with ADT and SBRT

  This study tests whether using PSMA-PET imaging during hormone therapy can help doctors target remaining cancer with a focused SBRT boost in men with intermediate- or high-risk prostate cancer.

  Recruiting at 2 sites Phase 2 Brigham and Women's Hospital · Boston, Massachusetts and 3 other locations · NCT07393867

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.